Atai life sciences launches innarisbio, in partnership with the university of queensland, with the aim to develop a more effective nose-to-brain delivery method for atai's platform of mental health therapeutic programs

Berlin and brisbane, australia, july 28, 2021 (globe newswire) -- atai life sciences (“atai” or the “company”) (nasdaq: atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and uniquest, australia's leading university technology transfer company commercializing the research of the university of queensland (uq), today announced the launch of innarisbio inc. (innarisbio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders.
ATAI Ratings Summary
ATAI Quant Ranking